Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

Bullboard Posts
Comment by Thehuntsmanon Aug 19, 2020 3:43pm
98 Views
Post# 31430302

RE:Enough with the bloody reverse split talk.

RE:Enough with the bloody reverse split talk.Thanks Nailz. Agree 100%. Check your inbox please.
Nailbiter1 wrote:

I wish people would stop worrying about the RS.
It is out of the question until after Q4 or the commercial rollout of Aristotle.

Management got 76.8% approval from investors to do a RS,
IF REQUIRED.

The reason they had to seek pre-approval at the AGM was because if they reach a SP that is strong enough to support a split to move to the US trading system, they could do it as quickly as possible.

If they had to ask approval from investors at the time that the SP is strong, every flip-flopper and his fkn' monkey would try to sell before the RS causing the SP to sink.

It won't happen just to stop penny-poppers in single digits.

Tripp mentioned in the CC that we will have more analysts coming on board.

As they start to chime in, we will see a better picture of Q3 and Q4.

I believe it will be a whole different ball game.

I can't say for sure but this is how I think the RS will go down.

Some day, in 2021, after Q4 and news on Aristotle, the stock will get halted.

"Hey, why are we halted"?

NEWS "management has decided to perform a RS in order to begin trading on the Nasdaq".

It will remain halted until everything is done and we apply for listing.
There are other facets involved in listing besides SP level.

This will take time but the RS itself will be done swiftly because of pre-approval voted at the AGM.

I voted for this approval and I know Tripp and Riggs and the rest of the board members will do it in a safe and profitable manner.

Out of sight and out of mind for now, PLEASE.

It will not happen when our stock includes a centavos symbol. There will be a "pieces of eight" symbol present.

"$"




Bullboard Posts